Gsk Novartis

• 

  GSK Set To Buy Novartis Stake In Joint Venture For $13 Billion, Might Lose Horlicks Brand

  Completion of the buyout by GSK of Novartis 36.5% stake in the joint venture is currently expected to occur during the summer of 2018.

• 

  GSK Buys Novartis Stake In Consumer Healthcare Venture For $13 billion

  The deal is set to complete in the second quarter subject to the necessary approvals.

• 

  In Fight For GSK's Advair, Generic Firms Step Carefully On Price

  Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they can win business without a race to the bottom on price.

• 

  Novartis India Q2 Net Rises to Rs 104 Crore

  The company's board in January had approved a slump sale of OTC business to GSK Consumer Private Limited.

• Novartis India Gets Nod to Sell OTC Business to GSK CPL

  Novartis India shares closed at Rs 799.5 apiece on BSE, down 0.88 per cent.

• 

  New-Look GSK Bets on Consumer Health Spending

  Emma Walmsley, head of the British drugmaker's enlarged consumer healthcare business, says its market-leading position in areas such as pain relief and oral health will bolster the division's margins and make it a partner of choice for retailers.

• Novartis Okays OTC Unit Sale to GSK Consumer

  The move follows a global deal struck in April last year, under which Swiss-based Novartis AG had agreed with UK-based GlaxoSmithKline plc to create a global consumer healthcare joint venture, GlaxoSmithKline Consumer Private Ltd (GSK CPL), as part of its global portfolio transformation.

• 

  Novartis India Gains 5% as CCI Clears Deal with GSK

  The multi-layered deal involves UK-based GlaxoSmithKline (GSK) acquiring the Swiss major's vaccine business while the latter would purchase GSK's cancer drugs portfolio.

• 

  Novartis-GSK Pharma Deal Cleared by CCI

  The Competition Commission of India (CCI) has approved a multi-billion dollar deal between global pharma giants GlaxoSmithKline Plc and Novartis, as it does not find the transaction to be anti-competitive in India.

• GSK says Novartis deal not to impact India business

  The two companies agreed to form a joint venture by combining Novartis' over-the-counter division with GSK's consumer business to create a business with $10 billion in annual sales. GSK will hold a 63.5 per cent stake in the venture.

• 

  Novartis reshapes business via deals with GSK and Lilly

  The overhaul is part of a major realignment in the global pharmaceuticals industry as it strives to cope with a clampdown in health spending by cash-strapped governments.

• Novartis India soars 20% on parent's deal with GSK, Eli Lilly

  Novartis will acquire GSK's oncology products for a $14.5 billion. In a separate transaction, it will divest its animal health division to Eli Lilly for approximately $5.4 billion.

• 2013: Few bitter pills, booster injections for pharma sector

  Domestic firms coming under increased scrutiny of global regulators, resulting in Ranbaxy paying a record $500-million fine, and drugs becoming cheaper in India thanks to a new pricing policy marked a roller-coaster year 2013 for the pharma industry.

• New drug pricing policy to impact multinational companies the most: Analysts

  The proposed draft pharma policy is likely to impact those multinational companies the most, which are in the premium pricing band, say analysts.